Showing results (31-40 of 293) with videos related to
Sort By:
Pageof 30
Health Affairs (Project Hope)|November 7, 2012
Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseasesAna M Valverde, Shelby D Reed, Kevin A SchulmanValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 4, 2019
The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative AssessmentsF Reed Johnson, Jui-Chen Yang, Shelby D ReedMedical Decision Making : an International Journal of the Society for Medical Decision Making|November 3, 2022
Method for Calculating the Simultaneous Maximum Acceptable Risk Threshold (SMART) from Discrete-Choice Experiment Benefit-Risk StudiesAngelyn Otteson Fairchild, Shelby D Reed, Juan Marcos GonzalezHeart Failure Clinics|September 20, 2011
End point selection in acute decompensated heart failure clinical trials: economic end pointsShelby D Reed, Zubin J Eapen, Kevin A SchulmanPharmacoeconomics|April 22, 2004
The economic burden of allergic rhinitis: a critical evaluation of the literatureShelby D Reed, Todd A Lee, Douglas C McCroryAntiviral Therapy|November 29, 2012
Economic evaluation of direct-acting antiviral therapy in chronic hepatitis CZiad F Gellad, Shelby D Reed, Andrew J MuirValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2006
Analytic considerations in economic evaluations of multinational cardiovascular clinical trialsFrank M Torti, Shelby D Reed, Kevin A SchulmanAllergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|May 2, 2018
Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record dataDon Husereau, Jason Goodfield, Richard Leigh, et al.BMC Health Services Research|October 12, 2024
Study on the concentration, distribution, and persistence of health spending for the contributory scheme in ColombiaOscar Espinosa, Rocco Friebel, Valeria Bejarano, et al.Pharmacoeconomics|November 8, 2017
Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology AssessmentJaclyn Beca, Don Husereau, Kelvin K W Chan, et al.Pageof 30